Equities

BrainCool AB (publ)

BrainCool AB (publ)

Actions
  • Price (SEK)1.74
  • Today's Change-0.056 / -3.11%
  • Shares traded437.54k
  • 1 Year change-1.10%
  • Beta1.2538
Data delayed at least 15 minutes, as of Apr 30 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BrainCool AB (publ) is a Sweden-based medical device company, that specializes in the development, marketing, and sale of medical cooling systems of the human brain. The Company's technology acts as cooling pads that are applied to different parts of the patient's body, where the system controls the body temperature and other movements. Its product portfolio includes the BrainCool System, Cooral System, and RhinoChill System, offering a range of medical cooling solutions. The combination of the BrainCool and RhinoChill Systems provides care solution from pre-hospital to patient discharge. Cooral System offers solution for improving patients' quality of life and presents healthcare providers with an effective means of oral mucositis reduction. The products are used in the treatment of various severe conditions such as stroke, cardiac arrest, concussion, and migraine.

  • Revenue in SEK (TTM)29.15m
  • Net income in SEK-57.05m
  • Incorporated2010
  • Employees22.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SpectraCure AB (publ)2.84m-20.44m259.34m15.00--2.00--91.22-0.2104-0.21040.02931.340.0185--17.28189,533.30-13.31-12.75-14.35-13.62435.56195.30-718.99-494.40----0.0492---3.30--19.46------
Scandinavian Medical Solutions A/S300.23m19.20m328.22m--16.972.7912.041.090.44790.44797.002.731.422.0017.46--9.05--15.48--25.83--6.39--0.406219.960.2776--72.98--7.49------
Micropos Medical AB (publ)1.64m-23.54m372.22m4.00--40.08--227.24-0.1663-0.16630.01170.06110.06060.05381.46---87.07-64.24-115.32-82.2786.75114.76-1,437.12-767.581.15--0.0429--50.245.94-26.57------
Boule Diagnostics AB571.33m25.08m392.21m228.0015.860.82567.490.68650.63680.636814.6412.230.75424.673.842,505,829.003.281.674.482.4043.6943.504.352.041.074.270.259142.244.246.1396.24-9.45-9.74--
Modulight Oyj47.14m-138.91m419.26m70.00--0.6424--8.89-0.2805-0.28050.0951.310.0566-0.39882.0557,500.00-16.67-8.39-17.64-9.10123.80114.69-294.66-56.817.48--0.1051---12.48-8.20-38.69--63.60--
Karolinska Development AB2.01m5.39m420.55m8.0078.760.340268.01208.810.020.020.00754.620.0016--2.21251,750.000.42923.370.43293.83----267.431,466.36----0.00250.00-12.43-8.10106.11-29.31----
BrainCool AB (publ)29.15m-57.05m456.10m22.00--3.76--15.65-0.2848-0.28480.14650.47920.24182.093.321,214,417.00-47.34-47.14-56.18-70.16-50.61-149.77-195.75-391.450.7253-7.340.00--32.0678.35-34.34---11.63--
Bioretec Oy45.76m-44.38m626.41m37.00--6.24--13.69-0.1984-0.19840.20470.42130.55241.463.68105,594.60-53.58-67.11-65.75-97.6069.8570.97-96.98-134.054.86-4.020.0754--32.7719.77-56.82------
Data as of Apr 30 2024. Currency figures normalised to BrainCool AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

4.28%Per cent of shares held by top holders
HolderShares% Held
Carnegie Fonder ABas of 29 Feb 20247.50m4.28%
Data from 28 Mar 2024 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.